TY - JOUR
T1 - Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status
AU - Xie, Yan
AU - Bowe, Benjamin
AU - Al-Aly, Ziyad
N1 - Funding Information:
This study used data from the VA COVID-19 Shared Data Resource. Disclaimer: The contents do not represent the views of the US Department of Veterans Affairs or the US government. Funding: This research was funded by the United States Department of Veterans Affairs (for Z.A.A.) and two American Society of Nephrology and KidneyCure fellowship awards (for Y.X. and B.B.).
Publisher Copyright:
© 2021, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2021/12
Y1 - 2021/12
N2 - The Post-Acute Sequelae of SARS-CoV-2 infection (PASC) have been characterized; however, the burden of PASC remains unknown. Here we used the healthcare databases of the US Department of Veterans Affairs to build a cohort of 181,384 people with COVID-19 and 4,397,509 non-infected controls and estimated that burden of PASC—defined as the presence of at least one sequela in excess of non-infected controls—was 73.43 (72.10, 74.72) per 1000 persons at 6 months. Burdens of individual sequelae varied by demographic groups (age, race, and sex) but were consistently higher in people with poorer baseline health and in those with more severe acute infection. In sum, the burden of PASC is substantial; PASC is non-monolithic with sequelae that are differentially expressed in various population groups. Collectively, our results may be useful in informing health systems capacity planning and care strategies of people with PASC.
AB - The Post-Acute Sequelae of SARS-CoV-2 infection (PASC) have been characterized; however, the burden of PASC remains unknown. Here we used the healthcare databases of the US Department of Veterans Affairs to build a cohort of 181,384 people with COVID-19 and 4,397,509 non-infected controls and estimated that burden of PASC—defined as the presence of at least one sequela in excess of non-infected controls—was 73.43 (72.10, 74.72) per 1000 persons at 6 months. Burdens of individual sequelae varied by demographic groups (age, race, and sex) but were consistently higher in people with poorer baseline health and in those with more severe acute infection. In sum, the burden of PASC is substantial; PASC is non-monolithic with sequelae that are differentially expressed in various population groups. Collectively, our results may be useful in informing health systems capacity planning and care strategies of people with PASC.
UR - http://www.scopus.com/inward/record.url?scp=85118988575&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-26513-3
DO - 10.1038/s41467-021-26513-3
M3 - Article
C2 - 34772922
AN - SCOPUS:85118988575
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 6571
ER -